Publication|Articles|September 24, 2025
Supplements and Featured Publications
- Long-Acting Injectable Administration In Schizophrenia With Insights From Genoa Healthcare® Pharmacy
Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia
Listen
0:00 / 0:00
Advertisement
This educational resource was sponsored by Johnson & Johnson.
In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable antipsychotic programs, which are designed to help improve access and adherence to medications for people living with a severe and persistent mental illness like schizophrenia.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
House Votes to Extend ACA Subsidies, Eyes Turn to Senate
2
Subjective and Objective Impacts of Ambulatory AI Scribes
3
Misalignment Between EHR Penicillin Allergy Flags, Allergist Assessments Signals Need for Improved Documentation
4
Tobacco Use Tied to Immunotherapy Response and Gastric Cancer Mortality
5
























































